ストックスクリーナーアプリを入手
2.11
1.44%
0.03
アフターアワーズ：
2.11
前日終値:
$2.08
開ける：
$2.025
24時間の取引高:
46,702
Relative Volume:
0.09
時価総額：
$172.30M
収益：
$3.91M
当期純損益:
$-206.53M
株価収益率:
-0.8499
EPS:
-2.4825
ネットキャッシュフロー:
$-167.78M
1週間 パフォーマンス:
-1.86%
1か月 パフォーマンス:
-14.23%
6か月 パフォーマンス:
+99.06%
1年 パフォーマンス:
+47.55%
1日の値動き範囲:
$2.025
$2.13
1週間の範囲:
$2.0107
$2.235
52週間の値動き範囲:
$0.595
$3.075
I Mab Adr Stock (IMAB) Company Profile
IMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMAB
I Mab Adr
|
2.11 | 169.85M | 3.91M | -206.53M | -167.78M | -2.4825 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
I Mab Adr Stock (IMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-09 | 開始されました | Siebert Williams Shank | Buy |
| 2021-06-02 | 開始されました | Daiwa Securities | Buy |
| 2021-03-15 | 開始されました | Needham | Buy |
| 2021-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-25 | 開始されました | Piper Sandler | Overweight |
| 2020-12-07 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-12 | 開始されました | China Renaissance | Buy |
| 2020-02-11 | 開始されました | Jefferies | Buy |
すべてを表示
I Mab Adr (IMAB) 最新ニュース
I-Mab acquires Bridge Health to strengthen givastomig development By Investing.com - Investing.com South Africa
I-Mab acquires Bridge Health to strengthen givastomig development - Investing.com India
Best Income Stocks to Buy for July 16th - The Globe and Mail
I-Mab to Present at the BTIG Virtual Biotechnology Conference - GlobeNewswire Inc.
I-MAB files 6-K to amend US$21M ADS shelf registration | BQ SEC FilingForm 6-K - Stock Titan
I-Mab reports 83% response rate for givastomig in gastric cancer study - Investing.com India
I-Mab’s givastomig shows promising results in gastric cancer study - Investing.com
I-Mab stock maintains buy rating at H.C. Wainwright on strong cancer data - Investing.com
I-Mab reports 71% response rate for gastric cancer drug in trial - Investing.com
H.C. Wainwright reiterates buy rating on I-Mab stock ahead of key data - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations - Investing.com
I-Mab at H.C. Wainwright: Strategic Shift Towards U.S. Operations By Investing.com - Investing.com South Africa
Market Momentum: Abpro Holdings Inc (ABP) Registers a 3.72 Increase, Closing at 0.22 - DWinneX
Unity Software Inc’s Market Journey: Closing Strong at 24.40, Up 3.13 - DWinneX
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross - MSN
I-Mab regains Nasdaq compliance as shares maintain $1 minimum bid - Investing.com India
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance
Figure 1. Protein and mRNA expressions of P-glycoprotein in BEL-7402... - researchgate.net
Willdan Group, Inc.'s (NASDAQ:WLDN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - Yahoo Finance
Can This Unstoppable Stock Join Microsoft, Nvidia, Apple, Amazon, Alphabet, Meta Platforms, and Tesla in the $1 Trillion Club? - Yahoo Finance
Graphjet Technology Discloses Notice from Nasdaq - Yahoo Finance
B. Riley Financial granted extension from Nasdaq regarding listing rules - Yahoo Finance
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy? - sharewise
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy - Yahoo Finance
Asian Stocks Shine As Biotech And Financials Lead Gains - Finimize
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - Yahoo Finance
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series - Yahoo Finance
I-Mab stock surges on Lucid Capital’s buy rating initiation By Investing.com - Investing.com South Africa
I-Mab stock surges on Lucid Capital’s buy rating initiation - Investing.com
Lucid Capital sets I-Mab stock Buy rating, $5 target on cancer drug potential - Investing.com
I-Mab’s Financial Report Highlights Givastomig Progress - TipRanks
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Barchart.com
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC - Barchart.com
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB) - Yahoo Finance
I-Mab at Needham Conference: Strategic Transformation Unveiled - Investing.com
I-Mab at Needham Conference: Strategic Transformation Unveiled By Investing.com - Investing.com South Africa
I-Mab’s Transformative Year: Financial and Strategic Highlights - TipRanks
I-Mab stock price target lowered to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
I-Mab stock price target lowered to $7 at H.C. Wainwright - Investing.com India
I-Mab stock touches 52-week low at $0.72 amid market challenges - Investing.com
I-Mab faces Nasdaq delisting over bid price rule By Investing.com - Investing.com South Africa
I-Mab faces Nasdaq delisting over bid price rule - Investing.com
I-Mab advances gastric cancer treatment with swift trial enrollment - Investing.com
I-Mab stock touches 52-week low at $0.76 amid market challenges - Investing.com India
I Mab Adr (IMAB) 財務データ
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):